)
injection site reaction (15.6%), injection site erythema (11.7%), injection site pain (6.5%),
headache (6.5%), nasopharyngitis (5.2%), acne (5.2%), and insomnia (5.2%).2
injection site reaction (13.7%), injection site pain (8.4%), injection site erythema (6.6%),
and COVID-19 (7.9%).2
ATTRIBUTES AND
CONSIDERATIONS
FOR DUPIXENT1
NO BOXED WARNING
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.
no known drug-to-drug interactions
Not metabolized through the liver or excreted
through the kidneys.
DUPIXENT IS NOT AN
IMMUNOSUPPRESSANT
NO REQUIREMENT FOR INITIAL LAB
TESTING OR ONGOING LAB MONITORING,
according to the Prescribing information
IMPORTANT SAFETY INFORMATION
SELECT WARNING AND PRECAUTION
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
QW, once weekly; TEAE, treatment-emergent adverse event.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the information you need to get started.